New Blood Marker Predicts Heart Disease Risk in Early Metabolic Syndrome

This nationwide Chinese study reveals a powerful new biomarker for predicting cardiovascular disease and death in people with early-stage metabolic dysfunction. Researchers followed 5,847 adults from the China Health and Retirement Longitudinal Study for up to 9 years, focusing on individuals with stages 0-3 of cardiovascular-kidney-metabolic (CKM) syndrome—the preclinical phases before major complications occur.

The CTI index combines C-reactive protein (inflammation marker) with triglycerides and fasting glucose (insulin resistance markers) into a single score. After comprehensive statistical analysis controlling for age, sex, lifestyle factors, and existing conditions, researchers found striking results: each 1-unit increase in CTI was associated with a 111% higher risk of death from any cause.

The relationship between CTI and cardiovascular disease showed a non-linear pattern—risk increased more sharply at higher CTI levels. Participants in the highest CTI tertile were older, had higher BMI, blood pressure, and glucose levels, plus more diabetes, hypertension, and dyslipidemia compared to the lowest tertile. The predictive power remained strong across different age groups, sexes, and glucose tolerance levels.

This research addresses a critical gap in early detection. Current cardiovascular risk assessment often misses people in the preclinical stages when interventions could be most effective. The CTI index uses readily available lab tests, making it practical for routine screening. The findings suggest that combining inflammation and metabolic markers provides superior risk prediction compared to individual biomarkers alone.

The study's strength lies in its large sample size, long follow-up period, and focus on the understudied early stages of metabolic dysfunction. However, the observational design cannot prove causation, and the findings need validation in other populations before widespread clinical adoption.